Hematopoietic stem cells and other hematopoietic cells show broad resistance to chemotherapeutic agents in vivo when overexpressing bcl-2

Experimental Hematology

Volumn 31, Issue 7, 2003, Pages 631-639

  Domen, Jos ^a,b   Weissman, Irving L ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; FLUOROURACIL; PROTEIN BCL 2; PROTEIN DERIVATIVE; PROTEIN LIN; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER RESISTANCE; CELL POPULATION; CELL PROLIFERATION; CELL PROTECTION; CELL TYPE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; DRUG SENSITIVITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; PURIFICATION; TRANSGENIC MOUSE; UPREGULATION; WILD TYPE;

MUS MUSCULUS;

EID: 0038722038     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(03)00084-5     Document Type: Article

References (54)

1. Mesner P.W. Jr., Budihardjo I.I., Kaufmann S.H. Chemotherapy-induced apoptosis. Adv Pharmacol. 41:1997;461-499.
2. Strober S., Weissman I.L. Immunosuppressive and tolerogenic effects of whole-body, total lymphoid, and regional irradiation. Salaman J.R. The Current Status of Modern Therapy. 1981;19-53 MTP Press, Lancaster, England.
3. Reed J.C. bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol. 34:1997;9-19.
4. Chao D.T., Korsmeyer S.J. bcl-2 family: regulators of cell death. Annu Rev Immunol. 16:1998;395-419.
5. Cory S., Adams J.M. The bcl-2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2:2002;647-656.
6. Mazel S., Burtrum D., Petrie H.T. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J Exp Med. 183:1996;2219-2226.
7. Domen J., Cheshier S.H., Weissman I.L. The role of apoptosis in the regulation of hematopoietic stem cells. Overexpression of bcl-2 increases both their number and repopulation potential. J Exp Med. 191:2000;253-264.
8. Hengartner M.O. The biochemistry of apoptosis. Nature. 407:2000;770-776.
9. McCubrey J.A., May W.S., Duronio V., Mufson A. Serine/threonine phosphorylation in cytokine signal transduction. Leukemia. 14:2000;9-21.
10. Srivastava R.K., Mi Q.S., Hardwick J.M., Longo D.L. Deletion of the loop region of bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA. 96:1999;3775-3780.
11. Domen J., Gandy K.L., Weissman I.L. Systemic overexpression of bcl-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation. Blood. 91:1998;2272-2282.
12. Ogilvy S., Metcalf D., Print C.G., Bath M.L., Harris A.W., Adams J.M. Constitutive bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci USA. 96:1999;14943-14948.
13. Domen J., Weissman I.L. Hematopoietic stem cells need two signals to prevent apoptosis; bcl-2 can provide one of these, Kitl/c-kit signaling the other. J Exp Med. 192:2000;1707-1718.
14. Reed J.C. bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Adv Pharmacol. 41:1997;501-532.
15. Herr I., Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood. 98:2001;2603-2614.
16. Schmitt C.A., Rosenthal C.T., Lowe S.W. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med. 6:2000;1029-1035.
17. Wuchter C., Karawajew L., Ruppert V., et al. Clinical significance of C.D.95, bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia. 13:1999;1943-1953.
18. Bincoletto C., Saad S.T., da Silva E.S., Queiroz M.L. Haematopoietic response and bcl-2 expression in patients with acute myeloid leukaemia. Eur J Haematol. 62:1999;38-42.
19. Karakas T., Maurer U., Weidmann E., Miething C.C., Hoelzer D., Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 9:1998;159-165.
20. Volm M., Zintl F., Sauerbrey A., Koomagi R. Proliferation and apoptosis in newly diagnosed and relapsed childhood acute lymphoblastic leukemia. Anticancer Res. 19:1999;4327-4331.
21. Pepper C., Thomas A., Hidalgo de Quintana J., Davies S., Hoy T., Bentley P. Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia - the role of bcl-2 family dysregulation. Leuk Res. 23:1999;1007-1014.
22. Stoetzer O.J., Pogrebniak A., Scholz M., et al. Drug-induced apoptosis in chronic lymphocytic leukemia. Leukemia. 13:1999;1873-1880.
23. Banker D.E., Groudine M., Norwood T., Appelbaum F.R. Measurement of spontaneous and therapeutic agent-induced apoptosis with bcl-2 protein expression in acute myeloid leukemia. Blood. 89:1997;243-255.
24. Naumovski L., Martinovsky G., Wong C., et al. bcl-2 expression does not correlate with patient outcome in pediatric acute myelogenous leukemia. Leuk Res. 22:1998;81-87.
25. Srinivas G., Kusumakumary P., Nair M.K., Panicker K.R., Pillai M.R. Mutant p53 protein, bcl-2/Bax ratios and apoptosis in paediatric acute lymphoblastic leukaemia. J Cancer Res Clin Oncol. 126:2000;62-67.
26. Christodoulopoulos G., Fotouhi N., Krajewski S., Reed J.C., Alaoui-Jamali M., Panasci L. Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of bcl-2, Bax, bcl-X and p53. Cancer Lett. 121:1997;59-67.
27. Johnston J.B., Daeninck P., Verburg L., et al. P53, MDM-2, BAX and bcl-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma. 26:1997;435-449.
28. Gregorc V., Ludovini V., Pistola L., et al. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 39:2003;41-48.
29. Lagasse E., Weissman I.L. Flow cytometric identification of murine neutrophils and monocytes. J Immunol Methods. 197:1996;139-150.
30. Ikuta K., Kina T., MacNeil I., et al. A developmental switch in thymic lymphocyte maturation potential occurs at the level of hematopoietic stem cells. Cell. 62:1990;863-874.
31. Li Y.S., Wasserman R., Hayakawa K., Hardy R.R. Identification of the earliest B lineage stage in mouse bone marrow. Immunity. 5:1996;527-535.
32. + maturation pathway in mouse thymic T cell development: lineages and selection. Immunity. 5:1996;147-161.
33. Scollay R.G., Butcher E.C., Weissman I.L. Thymus cell migration. Quantitative aspects of cellular traffic from the thymus to the periphery in mice. Eur J Immunol. 10:1980;210-218.
34. Szilvassy S.J., Cory S. Phenotypic and functional characterization of competitive long-term repopulating hematopoietic stem cells enriched from 5-fluorouracil-treated murine marrow. Blood. 81:1993;2310-2320.
35. Randall T.D., Weissman I.L. Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment. Blood. 89:1997;3596-3606.
36. Morrison S.J., Wright D.E., Weissman I.L. Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proc Natl Acad Sci USA. 94:1997;1908-1913.
37. Wright D.E., Cheshier S.H., Wagers A.J., Randall T.D., Christensen J.L., Weissman I.L. Cyclophosphamide/granulocyte colony-stimulating factorcauses selective mobilization of bone marrow hematopoietic stem cells into the blood after M phase of the cell cycle. Blood. 97:2001;2278-2285.
38. Morrison S.J., Weissman I.L. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity. 1:1994;661-673.
39. Campos L., Oriol P., Sabido O., Guyotat D. Simultaneous expression of P-glycoprotein and bcl-2 in acute myeloid leukemia blast cells. Leuk Lymphoma. 27:1997;119-125.
40. Kasimir-Bauer S., Ottinger H., Meusers P., et al. In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy. Exp Hematol. 26:1998;1111-1117.
41. Ohmori T., Podack E.R., Nishio K., et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun. 192:1993;30-36.
42. Miyashita T., Reed J.C. bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 81:1993;151-157.
43. Miyake H., Hara I., Yamanaka K., Arakawa S., Kamidono S. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and bcl-2. J Urol. 162:1999;2176-2181.
44. Liu R., Page C., Beidler D.R., Wicha M.S., Nunez G. Overexpression of bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model. Am J Pathol. 155:1999;1861-1867.
45. Schmitt C.A., Lowe S.W. bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. Blood Cells Mol Dis. 27:2001;206-216.
46. Felix K., Rolink A., Melchers F., Janz S. bcl-2 reduces mutant rates in a transgenic lacZ reporter gene in mouse pre-B lymphocytes. Mutat Res. 522:2003;135-144.
47. Saintigny Y., Dumay A., Lambert S., Lopez B.S. A novel role for the bcl-2 protein family: specific suppression of the RAD51 recombination pathway. EMBO J. 20:2001;2596-2607.
48. low pluripotent hemopoietic stem cells form CFU-S on day 16. Stem Cells. 17:1999;39-44.
49. Wang J.L., Liu D., Zhang Z.J., et al. Structure-based discovery of an organic compound that binds bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA. 97:2000;7124-7129.
50. Klasa R.J., Gillum A.M., Klem R.E., Frankel S.R. Oblimersen bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12:2002;193-213.
51. Marcucci G., Byrd J.C., Dai G., et al. Phase 1 and pharmacodynamic studies of G3139, a bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 101:2003;425-432.
52. Dorai T., Goluboff E.T., Olsson C.A., Buttyan R. Development of a hammerhead ribozyme against bcl-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. Anticancer Res. 17:1997;3307-3312.
53. Piche A., Grim J., Rancourt C., Gomez-Navarro J., Reed J.C., Curiel D.T. Modulation of bcl-2 protein levels by an intracellular anti-bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res. 58:1998;2134-2140.
54. Domen J., Weissman I.L. Self-renewal, differentiation or death: regulation and manipulation of hematopoietic stem cell fate. Mol Med Today. 5:1999;201-208.